Metformax Sr Combi

Metformin Hydrochloride and Sitagliptin, the active ingredient in Metformax Sr Combi, is a biguanide and DPP‑4 inhibitor presented as a tablet for oral use. It is prescribed to improve blood glucose control in adults with chronic type 2 diabetes mellitus.

GNH USA supplies Metformax Sr Combi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformax Sr Combi, containing metformin and sitagliptin, is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder.

- Type 2 diabetes mellitus: improves glycemic control when diet and exercise alone are insufficient. - Combination therapy with other oral antidiabetics: enhances overall glucose‑lowering effect. - Adjunct to lifestyle modification: supports weight management and metabolic health. - Monotherapy in patients intolerant to single agents: provides dual mechanism in a single pill.

Metformax Sr Combi may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea - Diarrhea - Abdominal discomfort

Serious or Rare Side Effects: - Lactic acidosis - Severe hypoglycemia (especially with insulin or sulfonylureas) - Acute pancreatitis

When prescribing Metformax Sr Combi, several safety considerations should be observed.

- Renal function: assess creatinine clearance before initiation and periodically thereafter. - Hepatic function: avoid use in patients with significant liver disease. - Lactic acidosis risk: contraindicated in severe renal impairment, heart failure, or hypoxia. - Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant. - Drug interactions: review concomitant medications that affect renal clearance or glucose levels. - Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Metformax Sr Combi can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Concomitant insulin or sulfonylureas: increased risk of severe hypoglycemia. - Iodinated contrast agents: may precipitate renal dysfunction and lactic acidosis. - Cimetidine: can raise metformin plasma concentrations.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: monitor renal function and potassium levels. - Loop or thiazide diuretics: may affect renal clearance of metformin. - Alcohol consumption: can increase risk of lactic acidosis.